August 26, 2021, TBDWG Meeting (online)

August 26, 2021

Meeting Materials

During this meeting, TBDWG members will focus on plans to develop the next report due December 2022 on federal tick-borne activities and research, taking into consideration the 2018 and 2020 reports.

Federal Register Notice

Written Public Comment

Meeting Summary

AGENDA
Time Meeting Item Presenter
9:00 am – 9:10 am Welcome from the Working Group Co-chairs and overview of the agenda Co-Chair Co-Chair
9:10 am – 9:40 am Official Welcome and Swearing in of Members Jim Berger, HHS/OASH
Designated Federal Officer

Dr. Rachel L. Levine
Assistant Secretary for Health (OASH)
9:40 am – 10:10 am Member Introductions Working Group Members
10:10 am – 10:15 am Overview of the Working Group’s Mission, Vision Statement, Values Jim Berger, DFO
10:15 am – 10:20 am Review of Charter, Roles and Responsibilities of the Working Group and Voting Procedures Jim Berger, DFO
10:20 am – 10:35 am Discuss 2022 TBDWG Objective Co-Chair Co-Chair
10:35 am – 10:45 am BREAK  
10:45 am – 11:30 am Public Comments  
11:30 am – 12:15 pm
  • National Strategy for Vector-Borne Disease Prevention and Control
  • LymeX update
    • Kristen Honey, HHS
 
12:15 pm – 1:00 pm Lunch  
1:00 pm – 1:30 pm Discussion on timeline for the 2022 TBDWG Report to Congress Co-Chair Co-Chair
1:30 pm – 1:45 pm Public Comment Subcommittee Discussion
  • Is there agreement to keep the subcommittee
  • Ask for volunteers for subcommittee
Co-Chair Co-Chair
1:45 pm – 4:30 pm Discuss report topics, ideas and potential subcommittees
  • Federal Inventory Subcommittee Discussion
  • Discuss and Vote on Need for Subcommittee Types and Number of Subcommittees
– call for vote, if ready
  • Discuss and Vote on Processes for:
    - Identification of Subcommittee Members and
        Selection of Subcommittee Members
    - How to Ensure Membership is a Balanced
       Coordination of Efforts with Working Group
Co-Chair Co-Chair
4:30 pm – 4:45 pm Recap of decisions made
Next Steps
 
4:45 pm Adjourn  
Content created by Office of Infectious Disease and HIV/AIDS Policy (OIDP)
Content last reviewed